This ⁣report summarizes findings from a retrospective study presented ⁣at the 43rd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) regarding a novel eye drop treatment for presbyopia (age-related ⁣difficulty focusing on⁤ near ⁣objects).

Key facts:

* Presbyopia: A common age-related condition affecting near vision, often requiring reading glasses.

* Study Type: Retrospective study of 766 patients.

* Presentation Date: September⁢ 14th at the ESCRS Congress.

* Focus: ⁣Providing a⁤ non-invasive choice to reading glasses or surgery for presbyopia sufferers.

* Pilocarpine: Constricts pupils and contracts the ciliary muscle (improves accommodation). Concentrations tested were 1%,2%,and 3%.

* ⁣ Diclofenac: A non-steroidal anti-inflammatory drug (NSAID) ⁤to reduce discomfort caused by pilocarpine.

Results - Improvement in Near Vision (Jaeger Chart):

The following table⁢ summarizes the percentage of⁤ patients achieving ⁤specific improvements in Jaeger chart ⁤lines read without reading glasses:

* Average Improvement: 3.45 Jaeger lines one hour after the first dose.

* Sustained Improvement: Improvement lasted up to two years (median duration 434 days).

* ⁤ Functional Near Vision: approximately 83% of ⁣all patients maintained ⁢good functional near⁤ vision at 12 months.

The study ⁣suggests that these eye drops offer a⁢ promising,⁣ non-invasive, and effective treatment option for presbyopia,⁤ wiht rapid and sustained improvements ⁢in near⁣ vision and a favorable safety profile.